BHH member Teamit Research participates in the Health Outcomes Observatory (H20) project which focuses on the creation of an innovative, ethical framework to collect and govern patient reported outcomes in Europe and beyond. By strengthening the patients voice, this European initiative aims to improve health care outcomes and sustainability. The project is led by the pharmaceutical company Takeda and coordinated by the Medical University of Vienna. The H20 Consortium is formed by 23 partners from both the public and private sector.
The Health Outcomes Observatory (H20) project has just started working in the design of an innovate framework to allow health data to be collected and used in a structured, ethical, and meaningful way with a view to generate a positive impact on a wide community of stakeholders: from patients and health care professionals to researchers, the industry, IT specialists, or health authorities. H2O intends to give patients in Europe a bigger and more influential voice in their individual and collective health care. At the same time, structured data on outcomes reported by patients can contribute to advance research, support a value- based approach in health care systems and ensure that new drugs under development are more patient friendly.
Furthermore, the project which has recently started will set up independent organisations – the observatories – in four European countries (Austria, Germany, the Netherlands and Spain), initially focused on diabetes, inflammatory bowel disease and oncology. H20 aims to eventually launch observatories throughout Europe, covering many more disease categories, which will be guided by a pan-European umbrella Observatory. This is the first-ever attempt at scale to collect and incorporate patient outcomes into healthcare decision making at an individual and population level across Europe and beyond.
H20 is funded by the Innovative Medicines Initiative (IMI), the world’s biggest public-private partnership in life sciences, backed by the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Trial Nation and Diabetes Research Funding (JDRF). The project has a total budget of € 20.4 Million and will conclude in 2025. The H20 Consortium is formed by an alliance of 23 partners from both the public and private sector.
Teamit Research was involved in writing the proposal, building the partnership, and negotiating the Grant Agreement and it will now have an active role in the strategic direction and management of the project. It will also bring its expertise in sustainability and the design and implementation of the communication and dissemination strategy.